secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2026-05-14T20:10:17+00:00
Accession:  0001193125-26-224022
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q1 revenue $19.3M (+4% YoY); net loss narrows to $10.6M
---------------------------------------------------------------------

- Total revenue $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx and improved RECELL utilization.
- Net loss $10.6M ($0.35 loss per share) vs $13.9M ($0.53 loss) in Q1 2025; operating expenses down 11% to $24.5M.
- Gross profit margin 81.7% (vs 84.7%) due to product mix; RECELL-only margin 85.0%.
- Reaffirmed FY2026 revenue guidance $80-85M, representing growth of 12-19%.
- Appointed Cary Vance as President and CEO; Jan Stern Reed as independent Chair of the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312526224022/0001193125-26-224022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312526224022/rcel-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-224022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer